Akagi Satoshi, Nakamura Kazufumi, Akagi Teiji, Nakagawa Koji, Takaya Yoichi, Sarashina Toshihiro, Ejiri Kentaro, Ito Hiroshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama 700-8558,
Acta Med Okayama. 2016 Oct;70(5):397-400. doi: 10.18926/AMO/54600.
A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.
肺动脉高压（PH）合并房间隔缺损（ASD）患者的治疗策略仍不明确。本研究旨在评估先行ASD初始修复，然后用PH特异性药物治疗对PH合并ASD患者的影响。符合条件的患者接受经导管ASD封堵术，随后用波生坦和西地那非治疗。在基线以及第12、24和48周时进行右心导管检查。主要终点是从基线到随访期间肺动脉压和肺血管阻力的变化。本研究应为制定PH合并ASD的治疗策略提供有价值的信息。
